MX366993B - Combinaciones con un peptido ciclado con la estructura de la base. - Google Patents
Combinaciones con un peptido ciclado con la estructura de la base.Info
- Publication number
- MX366993B MX366993B MX2015001684A MX2015001684A MX366993B MX 366993 B MX366993 B MX 366993B MX 2015001684 A MX2015001684 A MX 2015001684A MX 2015001684 A MX2015001684 A MX 2015001684A MX 366993 B MX366993 B MX 366993B
- Authority
- MX
- Mexico
- Prior art keywords
- dab
- diseases
- infections
- trp
- backbone
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001860 Eye Infections Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000036209 Intraabdominal Infections Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000005141 Otitis Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010062255 Soft tissue infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 208000037815 bloodstream infection Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000019258 ear infection Diseases 0.000 abstract 1
- 208000011323 eye infectious disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010040872 skin infection Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a una combinación novedosa que comprende un péptidomimético de ß-horquilla de la fórmula (Thr-Trp-Ile-Dab-Orn-DDAB-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), y otro compuesto con actividad antibiótica, que permiten el control terapéutico de infecciones bacterianas específicas en humanos o animales a dosis de los compuestos individuales más bajos que cualquiera de los compuestos administrados solos. La combinación se puede utilizar como un medicamento para tratar por ejemplo, infecciones de la piel o tejidos blandos; infecciones de ojos, oídos, torrente sanguíneo, o intra-abdominales; infecciones relacionadas con enfermedades respiratorias, enfermedades óseas, enfermedades cardiovasculares, enfermedades genitourinales, o enfermedades gastrointestinales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12005743 | 2012-08-08 | ||
| PCT/EP2013/066551 WO2014023766A1 (en) | 2012-08-08 | 2013-08-07 | Combinations with a backbone-cyclized peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015001684A MX2015001684A (es) | 2015-04-10 |
| MX366993B true MX366993B (es) | 2019-08-02 |
Family
ID=46796225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015001684A MX366993B (es) | 2012-08-08 | 2013-08-07 | Combinaciones con un peptido ciclado con la estructura de la base. |
| MX2019002894A MX2019002894A (es) | 2012-08-08 | 2015-02-06 | Combinaciones con un peptido ciclado con la estructura de la base. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002894A MX2019002894A (es) | 2012-08-08 | 2015-02-06 | Combinaciones con un peptido ciclado con la estructura de la base. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9814754B2 (es) |
| EP (1) | EP2882771B1 (es) |
| JP (2) | JP6486271B2 (es) |
| KR (1) | KR102142870B1 (es) |
| CN (1) | CN104684924B (es) |
| AU (1) | AU2013301576B2 (es) |
| BR (1) | BR112015002726B1 (es) |
| CA (1) | CA2887388C (es) |
| CY (1) | CY1120727T1 (es) |
| DK (1) | DK2882771T3 (es) |
| EA (1) | EA030524B1 (es) |
| ES (1) | ES2640289T3 (es) |
| HR (1) | HRP20171385T1 (es) |
| HU (1) | HUE036289T2 (es) |
| IL (1) | IL236696B (es) |
| LT (1) | LT2882771T (es) |
| MX (2) | MX366993B (es) |
| NZ (1) | NZ703723A (es) |
| PL (1) | PL2882771T3 (es) |
| PT (1) | PT2882771T (es) |
| RS (1) | RS56350B1 (es) |
| SG (1) | SG11201500130WA (es) |
| SI (1) | SI2882771T1 (es) |
| WO (1) | WO2014023766A1 (es) |
| ZA (1) | ZA201500277B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009008843A (es) | 2007-02-28 | 2009-08-28 | Polyphor Ltd | Peptidomimeticos fijados a un patron. |
| KR101692992B1 (ko) | 2015-05-20 | 2017-01-17 | 연세대학교 산학협력단 | 고리형 펩타이드의 사전 활성화 합성방법 및 이에 따라 합성된 고리형 펩타이드 |
| KR20230123950A (ko) * | 2020-11-23 | 2023-08-24 | 스펙시스 아게 | 베타-헤어핀 펩티도미메틱의 조성물 및 이의 에어로졸 투여 형태 |
| CN116782879A (zh) * | 2020-11-23 | 2023-09-19 | 斯佩希斯股份公司 | β-发夹素拟肽的组合物及其气雾剂剂型 |
| CN122036889B (zh) * | 2026-04-15 | 2026-07-24 | 湖北江夏实验室 | 一种靶向多重耐药肺炎克雷伯菌的环化抗菌肽CycP-1、其组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003232253A1 (en) * | 2003-05-02 | 2004-11-23 | Polyphor Ag | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
| WO2007079597A1 (en) * | 2006-01-16 | 2007-07-19 | Polyphor Ltd. | Template - fixed peptidomimetics with antimicrobial activity |
| WO2010017273A2 (en) | 2008-08-06 | 2010-02-11 | Wyeth | Tigecycline formulations |
-
2013
- 2013-08-07 MX MX2015001684A patent/MX366993B/es active IP Right Grant
- 2013-08-07 HR HRP20171385TT patent/HRP20171385T1/hr unknown
- 2013-08-07 BR BR112015002726-1A patent/BR112015002726B1/pt not_active IP Right Cessation
- 2013-08-07 SI SI201330766T patent/SI2882771T1/sl unknown
- 2013-08-07 EA EA201590350A patent/EA030524B1/ru unknown
- 2013-08-07 EP EP13745848.5A patent/EP2882771B1/en active Active
- 2013-08-07 HU HUE13745848A patent/HUE036289T2/hu unknown
- 2013-08-07 US US14/419,992 patent/US9814754B2/en not_active Expired - Fee Related
- 2013-08-07 LT LTEP13745848.5T patent/LT2882771T/lt unknown
- 2013-08-07 WO PCT/EP2013/066551 patent/WO2014023766A1/en not_active Ceased
- 2013-08-07 DK DK13745848.5T patent/DK2882771T3/en active
- 2013-08-07 CN CN201380041531.9A patent/CN104684924B/zh not_active Expired - Fee Related
- 2013-08-07 CA CA2887388A patent/CA2887388C/en active Active
- 2013-08-07 SG SG11201500130WA patent/SG11201500130WA/en unknown
- 2013-08-07 PL PL13745848T patent/PL2882771T3/pl unknown
- 2013-08-07 AU AU2013301576A patent/AU2013301576B2/en not_active Ceased
- 2013-08-07 JP JP2015525879A patent/JP6486271B2/ja not_active Expired - Fee Related
- 2013-08-07 KR KR1020157005846A patent/KR102142870B1/ko not_active Expired - Fee Related
- 2013-08-07 PT PT137458485T patent/PT2882771T/pt unknown
- 2013-08-07 RS RS20170908A patent/RS56350B1/sr unknown
- 2013-08-07 ES ES13745848.5T patent/ES2640289T3/es active Active
- 2013-08-07 NZ NZ703723A patent/NZ703723A/en not_active IP Right Cessation
-
2015
- 2015-01-13 IL IL236696A patent/IL236696B/en active IP Right Grant
- 2015-01-14 ZA ZA2015/00277A patent/ZA201500277B/en unknown
- 2015-02-06 MX MX2019002894A patent/MX2019002894A/es unknown
-
2017
- 2017-09-01 CY CY171100928T patent/CY1120727T1/el unknown
-
2018
- 2018-02-02 JP JP2018016953A patent/JP2018109008A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA104320C2 (ru) | Фармацевтическая композиция на основе митохондриально-адресованного антиоксиданта для применения в медицинской и ветеринарной офтальмологии | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| NZ701607A (en) | Therapeutic use of chardonnay seed products | |
| WO2009043458A3 (en) | Use of oxytocin to treat many diseases | |
| MX337830B (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. | |
| NZ605841A (en) | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine | |
| NZ604662A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine | |
| BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| ATE553772T1 (de) | Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| MX2019002894A (es) | Combinaciones con un peptido ciclado con la estructura de la base. | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| WO2009046864A3 (en) | Use of the human pancreatic polypeptide as a therapeutic agent | |
| MX2019002657A (es) | Combinaciones con un peptido con esqueleto ciclado. | |
| MX2015016750A (es) | Composicion inmunogenica para uso en terapia. | |
| WO2011056871A3 (en) | Rhamnolipid mechanism | |
| WO2009046860A3 (en) | Use of dago as a therapeutic agent | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| PH12014500561A1 (en) | Phenyl derivative | |
| IN2014CN03333A (es) | ||
| EA201791895A1 (ru) | Дозы и способы введения телаванцина | |
| MY170190A (en) | Use of a fermented soy extract as a prebiotic composition | |
| EA201200753A1 (ru) | Фармацевтическая композиция для лечения заболеваний мочевого пузыря |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |